All filters
Slidesets
(Abstract) Antiviral Activity of Tenofovir Alafenamide (TAF) against HIV-1 Subtypes and Emergence of K65R | Dr. C. Callebaut
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death | Dr. A. Battisti
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Clinical impact of vaccine-escape HBsAg mutants in HBV-infected patients: high rate of atypical serological profiles and increased level of viremia and transaminases | Dr. R. Salpini
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression | Dr. L. Colagrossi
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Community perspective | Rebekah Webb
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Roadblocks to implementation | Pep Coll, MD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Maintenance Therapy - What is the scientific/ virological rational | Charles Boucher, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
HIV attachment Inhibitors - Educational lecture in collaboration with ESAR | Thomas Klimkait, MD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
PI remain important options for first line | Linos Vandekerckhove, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Improving PI drug resistance scores | Jens Verheyen, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Breakthrough of preexisting X4-tropic HIV after allogeneic stem-cell transplantation | Dr. J. Verheyen
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Ex vivo determination of stem cell transplantation graft-versus-HIV reservoir effects | Dr. L. Hogan
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Potent Activity of GS-9883, a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance | Dr. K. White
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
HIV in Europe 2020 – what will it look like? | Carlo Federico Perno, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Dolutegravir plus Rilpivirine in cART-Experienced Subjects: a cohort study | Dr. G. Sterrantino
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects | Dr. G. Sterrantino
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine single tablet regimen | Dr. D. Di Carlo
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Next generation sequencing in routine HIV-1 resistance diagnostic - frequency of additional resistance relevant mutations in 2% and 1% population | Dr. R. Ehret
Presented at:
European Meeting on HIV & Hepatitis 2016